Korea reimburses Ozempic but moves to shut off self-pay loopholes

Korea’s national health insurance system is built on a simple bargain: if the government decides a drug is worth paying for, patients get access -- and if they want something outside the rules, they can usually pay out of pocket.

Ozempic has arrived as an exception.

On Sunday, the Ministry of Health and Welfare began reimbursing Ozempic, Novo Nordisk Pharma Korea’s type 2 diabetes injection made with semaglutide, the same active ingredient as its weight-loss sister drug, Wegovy.

The listing ended months of anticipation. It also crystallized the government’s real objective.

This was not just about paying for a diabetes drug. It was also about controlling what happens when a diabetes drug is a weight-loss prize.

(Courtesy of Novo Nordisk Pharma Korea)

The ministry’s reimbursement notice does what Korean reimbursement notices usually do -- it defines who qualifies, under what combinations, and with what follow-up.

But it also does something Korean clinicians say is far rarer: it effectively turns reimbursement criteria into a boundary around prescribing itself.

Under the policy framework described in ministry guidance, Ozempic use outside the listed coverage criteria is not simply “non-covered” in the ordinary sense. Doctors say it is treated as effectively impermissible, even if a patient is willing to pay the full cost.

“That’s probably the biggest part,” said Park Jung-hwan, who leads external cooperation and policy work at the Korean Society for the Study of Obesity, in a phone interview with Korea Biomedical Review on Monday.

He said the fiercest controversy has not been whether Ozempic should be reimbursed, but whether the government should block the familiar pressure valve of “100 percent self-pay.”

Ozempic’s path to reimbursement was watched closely long before the Sunday listing. In the fall, Novo Nordisk said it would begin supplying Ozempic in Korea as a non-reimbursed product while coverage review moved through the Health Insurance Review and Assessment Service and toward Korea’s reimbursement evaluation process. The company framed the early supply as a way to widen access for type 2 diabetes patients.

At the same time, health officials were signaling that GLP-1 drugs were not just a reimbursement decision; they were a governance problem, one that would require tighter oversight and monitoring as prescribing surged and misuse allegations grew.

The ministry’s final structure reflects that posture. Coverage is recognized for specific combination regimens, including triple therapy with metformin, a sulfonylurea and Ozempic, and a pathway pairing basal insulin with Ozempic, with eligibility tied to treatment history and glycemic control thresholds.

The policy also includes administrative requirements: documentation at initiation, repeated reporting at intervals, and limits on prescription duration early in treatment, when titration is expected.

To clinicians, the most revealing feature is not that criteria exist, but why they were built this way. Ozempic is approved for type 2 diabetes.

Yet the reimbursement gate is designed to deter an adjacent use case -- weight loss -- because semaglutide has been turned into a cultural artifact in Korea and elsewhere: scarce, expensive, coveted, and easily repurposed.

The government’s argument, in broad terms, is that a reimbursed Ozempic prescription could become a cheaper substitute for non-reimbursed obesity treatment. The ministry appears to want the benefit system to make that harder: clear criteria, limited regimens, and the ability to monitor use through claims data.

Park said he could see why officials would want to draw a hard line, especially as the system braces for the next entrant, Mounjaro (tirzepatide) from Eli Lilly.

He pointed to a practical vulnerability policymakers rarely name directly: private indemnity insurance.

If a drug is prescribed under a diabetes indication, he said, insurers can end up paying even when the patient’s true goal is weight loss. Allowing broad discretionary self-pay prescribing under the diabetes label risks turning clinical intent into financial arbitrage.

But Park also said parts of the policy feel hard to defend clinically. One concern is rigidity: the criteria emphasize a fixed step sequence -- for example, requiring specific prior combination therapy -- in a way that doesn’t always reflect real-world practice.

Another is the use of BMI as a gate. “There’s no evidence that you shouldn’t use this drug just because BMI is low,” he said. In diabetes care, GLP-1 therapy can be justified for reasons unrelated to body weight, including broader cardiometabolic risk.

The stricter design also creates a paradox that doctors think will become clearer only after the policy is stress-tested.

Obesity treatment in Korea largely sits outside reimbursement. Diabetes treatment sits inside it.

If Ozempic becomes tightly constrained only within the diabetes channel, and if it is effectively barred outside the reimbursed criteria even on a full self-pay basis, the system could end up restricting some diabetes patients more sharply than it restricts weight-loss demand routed through non-covered care elsewhere.

Ozempic’s criteria are also being read as a template. Park said it is “very likely” that Mounjaro will face a similar reimbursement framework if it is listed for type 2 diabetes.

He said he suspected Ozempic’s approach was drafted with Mounjaro in mind, not only because policymakers anticipate the same misuse dynamics, but because administrators are often motivated by a quieter fear: accusations of favoritism.

If one product is seen as receiving more permissive coverage than a rival, competitors can argue the government has tilted the playing field.

In that sense, Ozempic’s reimbursement was never only about Ozempic. It was a test case for how the state will handle incretin drugs as a category, one that now straddles two indications, two markets and two different kinds of demand.

For now, Korea has done what it set out to do: it has reimbursed Ozempic for some diabetes patients.

But it has done it in a way that exposes the government’s underlying priority, building a gate and a monitoring regime strong enough to withstand the next wave of demand, including the one that may arrive when Mounjaro reaches the reimbursement finish line.